Katalin "Kati" Karikó (, ; born 17 January 1955) is a Hungarian-American biochemist who specializes in ribonucleic acid (RNA)-mediated mechanisms, particularly in vitro-transcribed messenger RNA (mRNA) for protein replacement therapy. Karikó laid the scientific groundwork for mRNA vaccines, overcoming major obstacles and skepticism in the scientific community. Karikó received the Nobel Prize in Physiology or Medicine in 2023 for her work, along with American immunologist Drew Weissman.

Karikó spent more than two decades as a poorly supported researcher at the University of Pennsylvania, where she was an adjunct professor. Prior to winning the Nobel Prize, the University of Pennsylvania had demoted her, cut her pay, and described Karikó as "not of faculty quality"; she was never granted tenure. Karikó co-founded and was CEO of RNARx from 2006 to 2013. From 2013 to 2022, she was associated with BioNTech RNA Pharmaceuticals, first as a vice president and promoted to senior vice president in 2019. In 2022, she left BioNTech to devote more time to research. In 2021, she received an honorary doctorate from the University of Szeged in Hungary, where she has since become a professor.

Katalin Karikó

Karikó's work includes scientific research on RNA-mediated immune activation, resulting in the co-discovery with Drew Weissman of the nucleoside modifications that suppress the immunogenicity of RNA. This is seen as a further contribution to the therapeutic use of mRNA. Together with Weissman, she holds United States patents for the application of non-immunogenic, nucleoside-modified RNA. This technology has been licensed by BioNTech and Moderna to develop their protein replacement technologies, but it was also used for their COVID-19 vaccines.

Katalin Karikó

The messenger RNA-based technology developed by Karikó and the two most effective vaccines based on it, BioNTech/Pfizer and Moderna, have formed the basis for the effective and successful fight against SARS-CoV-2 virus worldwide and have contributed significantly to the containment of the COVID-19 pandemic. For their work, Karikó and Weissman have received numerous other awards besides the Nobel, including the Lasker–DeBakey Clinical Medical Research Award, Time Magazine's Hero of the Year 2021, and the Tang Prize Award in Biopharmaceutical Science in 2022.

Katalin Karikó

Early life and education

Katalin Karikó was born in Szolnok, and grew up in Kisújszállás, Hungary, in a small home without running water, a refrigerator, or television. Her father was a butcher, and her mother was a bookkeeper. She excelled in science during her primary education, earning third place in Hungary in a biology competition.

Karikó obtained a B.Sc. degree in biology in 1978 and her Ph.D. in biochemistry in 1982, both from the University of Szeged. She worked with Jenő Tomasz and continued her postdoctoral research at the Institute of Biochemistry, Biological Research Centre (BRC) of Hungary. From 1978 until 1985, she was listed as an intelligence asset by the Communist Hungarian secret police, something she says she was blackmailed into out of fear of repercussions on her career or reprisals against her father. She claims that she did not provide them with information nor was she active as an agent.

In 1985, her lab at the BRC lost its funding, and Karikó sought work at institutions in other countries. After being offered a research position by Robert J. Suhadolnik of Temple University, Karikó left Hungary for the United States with her husband and two-year-old daughter (and, smuggled inside her daughter's teddy bear, £900 that they had received from selling their car and buying British pounds on the black market).

Career

Between 1985 and 1988, Karikó served as a postdoctoral fellow at Temple University in Philadelphia. Karikó participated in a clinical trial in which patients with AIDS, hematologic diseases, and chronic fatigue syndrome were treated with double-stranded RNA (dsRNA). At the time, this was considered groundbreaking research, as the molecular mechanism of interferon induction by dsRNA was not known, although the antiviral and antineoplastic effects of interferon were well-documented.